Response Genetics Stock Today
| RGDXQ Stock | USD 0.0001 0.00 0.00% |
PerformanceWeakest
| Odds Of DistressStrong
|
Response Genetics is selling at 1.0E-4 as of the 26th of January 2026; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 1.0E-4. Response Genetics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of October 2025 and ending today, the 26th of January 2026. Click here to learn more.
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. The company has 38.8 M outstanding shares of which 78.1 K shares are at this time shorted by private and institutional investors with about 0.31 days to cover all short positions. More on Response Genetics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Response Pink Sheet Highlights
| Business Concentration | Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) |
Response Genetics [RGDXQ] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 116. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Response Genetics's market, we take the total number of its shares issued and multiply it by Response Genetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Response Genetics classifies itself under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 38.8 M outstanding shares of which 78.1 K shares are at this time shorted by private and institutional investors with about 0.31 days to cover all short positions.
Response Genetics has accumulated about 1.73 M in cash with (13.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Response Genetics Probability Of Bankruptcy
Response Stock Against Markets
Response Pink Sheet Analysis Notes
The company recorded a loss per share of 0.37. Response Genetics had not issued any dividends in recent years. Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. RESPONSE GENETICS operates under Diagnostics Research classification in the United States and is traded on PNK Exchange. It employs 96 people.The quote for Response Genetics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Response Genetics contact the company at 323-224-3900 or learn more at https://www.responsegenetics.com.Response Genetics Investment Alerts
| Response Genetics generated a negative expected return over the last 90 days | |
| Response Genetics has some characteristics of a very speculative penny stock | |
| Response Genetics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 18.04 M. Net Loss for the year was (20.18 M) with profit before overhead, payroll, taxes, and interest of 6.23 M. | |
| Response Genetics has accumulated about 1.73 M in cash with (13.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Response Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 116. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Response Genetics's market, we take the total number of its shares issued and multiply it by Response Genetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Response Profitablity
The company has Profit Margin (PM) of (0.86) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.82) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.82.Technical Drivers
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Response Genetics, as well as the relationship between them.Response Genetics Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Response Genetics Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Response Genetics price patterns.
Response Genetics Outstanding Bonds
Response Genetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Response Genetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Response bonds can be classified according to their maturity, which is the date when Response Genetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US76120HAA59 Corp BondUS76120HAA59 | View | |
| US76120HAC16 Corp BondUS76120HAC16 | View |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Response Genetics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
Additional Tools for Response Pink Sheet Analysis
When running Response Genetics' price analysis, check to measure Response Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Response Genetics is operating at the current time. Most of Response Genetics' value examination focuses on studying past and present price action to predict the probability of Response Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Response Genetics' price. Additionally, you may evaluate how the addition of Response Genetics to your portfolios can decrease your overall portfolio volatility.